These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 21718327)

  • 1. PET/CT in diagnosis of movement disorders.
    Berti V; Pupi A; Mosconi L
    Ann N Y Acad Sci; 2011 Jun; 1228():93-108. PubMed ID: 21718327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hybrid PET-MRI Applications in Movement Disorders.
    Tondo G; Esposito M; Dervenoulas G; Wilson H; Politis M; Pagano G
    Int Rev Neurobiol; 2019; 144():211-257. PubMed ID: 30638455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-photon emission computed tomography and positron emission tomography evaluations of patients with central motor disorders.
    Seibyl JP
    Semin Nucl Med; 2008 Jul; 38(4):274-86. PubMed ID: 18514083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of positron emission tomography imaging in movement disorders.
    Bohnen NI; Frey KA
    Neuroimaging Clin N Am; 2003 Nov; 13(4):791-803. PubMed ID: 15024962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PET/CT in diagnosis of dementia.
    Berti V; Pupi A; Mosconi L
    Ann N Y Acad Sci; 2011 Jun; 1228():81-92. PubMed ID: 21718326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2-Deoxy-2-[F-18]fluoro-D-glucose positron emission tomography/computed tomography in the management of melanoma.
    Iagaru A; Quon A; Johnson D; Gambhir SS; McDougall IR
    Mol Imaging Biol; 2007; 9(1):50-7. PubMed ID: 17051322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positron emission tomography applications in clinical neurology.
    Singhal T
    Semin Neurol; 2012 Sep; 32(4):421-31. PubMed ID: 23361486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Noninvasive assessment of pediatric inflammatory bowel disease with ¹⁸F-fluorodeoxyglucose-positron emission tomography and computed tomography.
    Däbritz J; Jasper N; Loeffler M; Weckesser M; Foell D
    Eur J Gastroenterol Hepatol; 2011 Jan; 23(1):81-9. PubMed ID: 21042220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PET/CT imaging in systemic lupus erythematosus.
    Curiel R; Akin EA; Beaulieu G; DePalma L; Hashefi M
    Ann N Y Acad Sci; 2011 Jun; 1228():71-80. PubMed ID: 21718325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PET Imaging in Movement Disorders.
    Maiti B; Perlmutter JS
    Semin Nucl Med; 2018 Nov; 48(6):513-524. PubMed ID: 30322477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain: positron emission tomography tracers beyond [¹⁸F]fluorodeoxyglucose.
    Singhal T; Alavi A; Kim CK
    PET Clin; 2014 Jul; 9(3):267-76. PubMed ID: 25030390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroimaging and therapeutics in movement disorders.
    Eckert T; Eidelberg D
    NeuroRx; 2005 Apr; 2(2):361-71. PubMed ID: 15897956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PET and movement disorders.
    Brooks DJ; Frackowiak RS
    J Neurol Neurosurg Psychiatry; 1989 Jun; Suppl(Suppl):68-77. PubMed ID: 2666580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular imaging (SPECT and PET) in the evaluation of patients with movement disorders.
    Gerasimou GP; Aggelopoulou TC; Costa DC; Gotzamani-Psarrakou A
    Nucl Med Rev Cent East Eur; 2006; 9(2):147-53. PubMed ID: 17304479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Value of functional imaging in Parkinson's disease and related movement disorders].
    Heiss WD; Würker M
    Nervenarzt; 1999 Jan; 70 Suppl 1():S2-10. PubMed ID: 10087524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The feasibility of statistical parametric mapping for the analysis of positron emission tomography studies using 11C-2-beta-carbomethoxy-3-beta-(4-fluorophenyl)-tropane in patients with movement disorders.
    Lucignani G; Gobbo C; Moresco RM; Antonini A; Panzacchi A; Bonaldi L; Carpinelli A; Caraceni T; Fazio F
    Nucl Med Commun; 2002 Nov; 23(11):1047-55. PubMed ID: 12411832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses.
    Ozülker T; Ozülker F; Ozbek E; Ozpaçaci T
    Nucl Med Commun; 2011 Apr; 32(4):265-72. PubMed ID: 21301376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging Transplantation in Movement Disorders.
    de Natale ER; Wilson H; Pagano G; Politis M
    Int Rev Neurobiol; 2018; 143():213-263. PubMed ID: 30473196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncologic PET/CT: current status and controversies.
    Siegel BA; Dehdashti F
    Eur Radiol; 2005 Nov; 15 Suppl 4():D127-32. PubMed ID: 16479662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.